BIOMARIN PHARMACEUTICAL INC Stock-Based Compensation
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Stock-Based Compensation of $119.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- BIOMARIN PHARMACEUTICAL INC share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $75.69M, a 59.25% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $43.46M, a 15.27% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $46.91M, a 9.64% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $49.27M, a 13.28% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC share-based payment arrangement, noncash expense for fiscal 2025 was $181.41M, a 10.00% decline from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC share-based payment arrangement, noncash expense for fiscal 2024 was $201.57M, a 2.67% decline from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC share-based payment arrangement, noncash expense for fiscal 2023 was $207.10M, a 5.50% increase from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC share-based payment arrangement, noncash expense for fiscal 2022 was $196.31M, a 0.48% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $75.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $119.15M 10-Q · filed 2026-08-06 | $166.06M derived: sum of 3 quarters · filed 2026-08-06 | $215.33M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $43.46M 10-Q · filed 2026-05-05 | $90.37M derived: sum of 2 quarters · filed 2026-05-05 | $139.64M derived: sum of 3 quarters · filed 2026-05-05 | $187.17M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $46.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $96.18M derived: sum of 2 quarters · filed 2026-02-26 | $143.71M derived: sum of 3 quarters · filed 2026-08-06 | $181.41M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $49.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $96.80M derived: sum of 2 quarters · filed 2026-08-06 | $134.50M 10-Q · filed 2025-10-28 | $186.41M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $47.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $85.23M 10-Q · filed 2026-08-06 | $137.15M derived: sum of 3 quarters · filed 2026-08-06 | $180.64M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $37.70M 10-Q · filed 2026-05-05 | $89.62M derived: sum of 2 quarters · filed 2026-05-05 | $133.11M derived: sum of 3 quarters · filed 2026-05-05 | $181.02M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $51.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $95.41M derived: sum of 2 quarters · filed 2026-02-26 | $143.32M derived: sum of 3 quarters · filed 2026-02-26 | $201.57M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $43.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $91.40M derived: sum of 2 quarters · filed 2025-10-28 | $149.65M 10-Q · filed 2025-10-28 | $204.51M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $47.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $106.16M 10-Q · filed 2025-08-05 | $161.02M derived: sum of 3 quarters · filed 2026-02-26 | $209.41M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $58.25M 10-Q · filed 2025-05-02 | $113.10M derived: sum of 2 quarters · filed 2026-02-26 | $161.49M derived: sum of 3 quarters · filed 2026-02-26 | $211.65M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $54.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $103.24M derived: sum of 2 quarters · filed 2026-02-26 | $153.40M derived: sum of 3 quarters · filed 2026-02-26 | $207.10M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $48.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $98.55M derived: sum of 2 quarters · filed 2024-10-31 | $152.24M 10-Q · filed 2024-10-31 | $198.98M derived: sum of 4 quarters · filed 2025-02-24 | ||||
| 2023-06-30 | $50.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $103.86M 10-Q · filed 2024-08-05 | $150.59M derived: sum of 3 quarters · filed 2025-02-24 | $205.25M derived: sum of 4 quarters · filed 2025-02-24 | ||||
| 2023-03-31 | $53.70M 10-Q · filed 2024-04-26 | $100.43M derived: sum of 2 quarters · filed 2025-02-24 | $155.09M derived: sum of 3 quarters · filed 2025-02-24 | $202.17M derived: sum of 4 quarters · filed 2025-02-24 | ||||
| 2022-12-31 | $46.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $101.40M derived: sum of 2 quarters · filed 2025-02-24 | $148.47M derived: sum of 3 quarters · filed 2025-02-24 | $196.31M 10-K · filed 2025-02-24 | ||||
| 2022-09-30 | $54.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $101.74M derived: sum of 2 quarters · filed 2023-11-02 | $149.57M 10-Q · filed 2023-11-02 | $193.47M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | $47.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $94.91M 10-Q · filed 2023-08-02 | $138.80M derived: sum of 3 quarters · filed 2024-02-26 | $187.83M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | $47.83M 10-Q · filed 2023-04-28 | $91.72M derived: sum of 2 quarters · filed 2024-02-26 | $140.75M derived: sum of 3 quarters · filed 2024-02-26 | $195.59M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | $43.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $92.92M derived: sum of 2 quarters · filed 2024-02-26 | $147.76M derived: sum of 3 quarters · filed 2024-02-26 | $197.26M 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | $49.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | $103.87M derived: sum of 2 quarters · filed 2022-10-28 | $153.37M 10-Q · filed 2022-10-28 | $200.96M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-06-30 | $54.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $104.35M 10-Q · filed 2022-08-04 | $151.93M derived: sum of 3 quarters · filed 2023-02-27 | $202.10M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-03-31 | $49.50M 10-Q · filed 2022-04-29 | $97.09M derived: sum of 2 quarters · filed 2023-02-27 | $147.26M derived: sum of 3 quarters · filed 2023-02-27 | $192.22M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2020-12-31 | $47.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $97.75M derived: sum of 2 quarters · filed 2023-02-27 | $142.72M derived: sum of 3 quarters · filed 2023-02-27 | $189.71M 10-K · filed 2023-02-27 | ||||
| 2020-09-30 | $50.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $95.13M derived: sum of 2 quarters · filed 2021-10-29 | $142.13M 10-Q · filed 2021-10-29 | $180.23M derived: sum of 4 quarters · filed 2022-02-25 | ||||
| 2020-06-30 | $44.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $91.96M 10-Q · filed 2021-07-30 | $130.06M derived: sum of 3 quarters · filed 2022-02-25 | $169.23M derived: sum of 4 quarters · filed 2022-02-25 | ||||
| 2020-03-31 | $46.99M 10-Q · filed 2021-04-30 | $85.10M derived: sum of 2 quarters · filed 2022-02-25 | $124.27M derived: sum of 3 quarters · filed 2022-02-25 | $164.10M derived: sum of 4 quarters · filed 2022-02-25 | ||||
| 2019-12-31 | $38.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $77.28M derived: sum of 2 quarters · filed 2022-02-25 | $117.10M derived: sum of 3 quarters · filed 2022-02-25 | $159.87M 10-K · filed 2022-02-25 | ||||
| 2019-09-30 | $39.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $79.00M derived: sum of 2 quarters · filed 2020-11-06 | $121.76M 10-Q · filed 2020-11-06 | $158.32M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-06-30 | $39.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $82.59M 10-Q · filed 2020-08-05 | $119.15M derived: sum of 3 quarters · filed 2021-02-26 | $156.19M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2019-03-31 | $42.76M 10-Q · filed 2020-05-01 | $79.32M derived: sum of 2 quarters · filed 2021-02-26 | $116.37M derived: sum of 3 quarters · filed 2021-02-26 | $154.97M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2018-12-31 | $36.56M derived: 10-K 12 month − 10-Q/A 9 month · filed 2021-02-26 | $73.61M derived: sum of 2 quarters · filed 2021-02-26 | $112.21M derived: sum of 3 quarters · filed 2021-02-26 | $148.82M 10-K · filed 2021-02-26 | ||||
| 2018-09-30 | $37.05M derived: 10-Q/A 9 month − 10-Q 6 month · filed 2019-11-04 | $75.65M derived: sum of 2 quarters · filed 2019-11-04 | $112.26M 10-Q/A · filed 2019-11-04 | $145.85M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | $38.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $75.21M 10-Q · filed 2019-08-02 | $108.80M derived: sum of 3 quarters · filed 2020-02-27 | $144.70M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $36.61M 10-Q · filed 2019-04-29 | $70.19M derived: sum of 2 quarters · filed 2020-02-27 | $106.10M derived: sum of 3 quarters · filed 2020-02-27 | $146.20M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $33.59M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $69.49M derived: sum of 2 quarters · filed 2020-02-27 | $109.59M derived: sum of 3 quarters · filed 2020-02-27 | $140.26M 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $35.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-26 | $76.00M derived: sum of 2 quarters · filed 2018-10-26 | $106.68M 10-Q · filed 2018-10-26 | $144.10M derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2017-06-30 | $40.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $70.78M 10-Q · filed 2018-08-03 | $108.20M derived: sum of 3 quarters · filed 2019-02-28 | $141.34M derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2017-03-31 | $30.67M 10-Q · filed 2018-04-27 | $68.09M derived: sum of 2 quarters · filed 2019-02-28 | $101.24M derived: sum of 3 quarters · filed 2019-02-28 | $135.14M derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2016-12-31 | $37.42M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $70.57M derived: sum of 2 quarters · filed 2019-02-28 | $104.46M derived: sum of 3 quarters · filed 2019-02-28 | $134.64M 10-K · filed 2019-02-28 | ||||
| 2016-09-30 | $33.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $67.04M derived: sum of 2 quarters · filed 2017-10-31 | $97.22M 10-Q · filed 2017-10-31 | $127.79M derived: sum of 4 quarters · filed 2018-02-26 | ||||
| 2016-06-30 | $33.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $64.08M 10-Q · filed 2017-08-02 | $94.64M derived: sum of 3 quarters · filed 2018-02-26 | $123.40M derived: sum of 4 quarters · filed 2018-02-26 | ||||
| 2016-03-31 | $30.18M 10-Q · filed 2017-05-04 | $60.74M derived: sum of 2 quarters · filed 2018-02-26 | $89.50M derived: sum of 3 quarters · filed 2018-02-26 | $119.01M derived: sum of 4 quarters · filed 2018-02-26 | ||||
| 2015-12-31 | $30.57M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $59.32M derived: sum of 2 quarters · filed 2018-02-26 | $88.83M derived: sum of 3 quarters · filed 2018-02-26 | $111.53M 10-K · filed 2018-02-26 | ||||
| 2015-09-30 | $28.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $58.27M derived: sum of 2 quarters · filed 2016-11-03 | $80.96M 10-Q · filed 2016-11-03 | $84.47M 10-Q · filed 2015-11-02 | $112.12M derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2015-06-30 | $29.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $52.20M 10-Q · filed 2016-08-08 | $54.40M 10-Q · filed 2015-08-05 | $83.36M derived: sum of 3 quarters · filed 2017-02-27 | $103.82M derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2015-03-31 | $22.69M 10-Q · filed 2016-05-02 | $23.71M 10-Q · filed 2015-05-05 | $53.85M derived: sum of 2 quarters · filed 2017-02-27 | $74.31M derived: sum of 3 quarters · filed 2017-02-27 | $91.83M derived: sum of 4 quarters · filed 2017-02-27 | |||
| 2014-12-31 | $31.16M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $51.62M derived: sum of 2 quarters · filed 2017-02-27 | $69.14M derived: sum of 3 quarters · filed 2017-02-27 | $86.41M 10-K · filed 2017-02-27 | $88.23M 10-K · filed 2015-03-02 | |||
| 2014-09-30 | $20.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | $37.98M derived: sum of 2 quarters · filed 2015-11-02 | $55.25M 10-Q · filed 2015-11-02 | $76.99M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $17.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $34.79M 10-Q · filed 2015-08-05 | $56.53M derived: sum of 3 quarters · filed 2016-02-29 | $73.32M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $17.27M 10-Q · filed 2015-05-05 | $39.01M derived: sum of 2 quarters · filed 2016-02-29 | $55.80M derived: sum of 3 quarters · filed 2016-02-29 | $70.14M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $21.74M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $38.53M derived: sum of 2 quarters · filed 2016-02-29 | $52.87M derived: sum of 3 quarters · filed 2016-02-29 | $64.38M 10-K · filed 2016-02-29 | $66.18M 10-K · filed 2014-02-26 | |||
| 2013-09-30 | $16.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $31.13M derived: sum of 2 quarters · filed 2014-10-28 | $42.64M 10-Q · filed 2014-10-28 | $54.56M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2013-06-30 | $14.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | $25.85M 10-Q · filed 2014-07-31 | $37.77M derived: sum of 3 quarters · filed 2015-03-02 | $49.76M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2013-03-31 | $11.51M 10-Q · filed 2014-05-02 | $23.43M derived: sum of 2 quarters · filed 2015-03-02 | $35.42M derived: sum of 3 quarters · filed 2015-03-02 | $47.69M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2012-12-31 | $11.93M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $23.92M derived: sum of 2 quarters · filed 2015-03-02 | $36.19M derived: sum of 3 quarters · filed 2015-03-02 | $47.34M 10-K · filed 2015-03-02 | ||||
| 2012-09-30 | $11.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | $24.26M derived: sum of 2 quarters · filed 2013-10-28 | $35.41M 10-Q · filed 2013-10-28 | $46.60M derived: sum of 4 quarters · filed 2014-02-26 | ||||
| 2012-06-30 | $12.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-29 | $23.42M 10-Q · filed 2013-07-29 | $34.61M derived: sum of 3 quarters · filed 2014-02-26 | $46.40M derived: sum of 4 quarters · filed 2014-02-26 | ||||
| 2012-03-31 | $11.15M 10-Q · filed 2013-04-29 | $22.34M derived: sum of 2 quarters · filed 2014-02-26 | $34.13M derived: sum of 3 quarters · filed 2014-02-26 | $44.91M derived: sum of 4 quarters · filed 2014-02-26 | ||||
| 2011-12-31 | $11.19M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-26 | $22.97M derived: sum of 2 quarters · filed 2014-02-26 | $33.76M derived: sum of 3 quarters · filed 2014-02-26 | $43.91M 10-K · filed 2014-02-26 | ||||
| 2011-09-30 | $11.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-29 | $22.57M derived: sum of 2 quarters · filed 2012-10-29 | $32.72M 10-Q · filed 2012-10-29 | $42.56M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | $10.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-02 | $20.94M 10-Q · filed 2012-08-02 | $30.77M derived: sum of 3 quarters · filed 2013-02-26 | $41.07M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $10.15M 10-Q · filed 2012-04-30 | $19.99M derived: sum of 2 quarters · filed 2013-02-26 | $30.28M derived: sum of 3 quarters · filed 2013-02-26 | $39.91M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2010-12-31 | $9.84M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $20.13M derived: sum of 2 quarters · filed 2013-02-26 | $29.76M derived: sum of 3 quarters · filed 2013-02-26 | $38.36M 10-K · filed 2013-02-26 | ||||
| 2010-09-30 | $10.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-31 | $19.92M derived: sum of 2 quarters · filed 2011-10-31 | $28.53M 10-Q · filed 2011-10-31 | $37.88M derived: sum of 4 quarters · filed 2012-02-22 | ||||
| 2010-06-30 | $9.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-01 | $18.23M 10-Q · filed 2011-08-01 | $27.59M derived: sum of 3 quarters · filed 2012-02-22 | $36.74M derived: sum of 4 quarters · filed 2012-02-22 | ||||
| 2010-03-31 | $8.61M 10-Q · filed 2011-04-29 | $17.96M derived: sum of 2 quarters · filed 2012-02-22 | $27.12M derived: sum of 3 quarters · filed 2012-02-22 | |||||
| 2009-12-31 | $9.36M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-22 | $18.51M derived: sum of 2 quarters · filed 2012-02-22 | $36.01M 10-K · filed 2012-02-22 | |||||
| 2009-09-30 | $9.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-29 | $26.65M 10-Q · filed 2010-10-29 | ||||||
| 2009-06-30 | $17.49M 10-Q · filed 2010-08-04 | |||||||
| 2008-12-31 | $28.34M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |